New single-dose vaccine trial results 'very encouraging'

Trials of a new vaccine to prevent coronavirus have produced extremely encouraging results.

Janssen’s new single Covid-19 vaccine, developed by the Johnson & Johnson-operated pharmaceutical company, has been shown to be 66 percent overall effective in preventing moderate to severe coronavirus 28 days after vaccination.
The announcement came less than 24 hours after the Novavax shock also appeared effective.
Professor Kevin Marsh, co-head of the Covid-19 team at the African Academy of Sciences and Professor of Tropical Medicine at Oxford University, said the results of the Janssen stab tests were “extremely encouraging”.

He said: “It is possible for some people to examine the overall reported 66% effectiveness in preventing moderate to severe Covid-19 and focus on comparisons with the potentially higher ‘top-line’ effectiveness that some others have Vaccines was reported.
“That would be a mistake. The real headline finding is that a single vaccine that can be easily stored and administered over the long term offers complete protection against hospitalizations and death.”
Janssen is continuing trials with two doses of its vaccine to see if it makes it even more effective.
The UK has ordered 30 million doses of the vaccine, with an option for an additional 22 million. Delivery is expected in the second half of this year, when the vaccine is approved by the Medicines and Health Products Regulatory Agency (MHRA).

Johnson & Johnson plans to apply for regulatory approval in the US next week, followed by an application for approval in Europe and the UK.
Health Secretary Matt Hancock tweeted, “This is even more good news from Janssen about vaccines.
“If this push is approved, it could significantly improve our vaccination program, especially as a single-dose vaccine.”
Three shocks that have already been approved in Great Britain – Pfizer / BioNTech, Moderna and Oxford / AstraZeneca as well as Novavax – could follow in a few weeks.
Novavax announced late Thursday that its shock was 89% effective after a clinical trial run in the UK.
About 60 million doses of the Novavax sting to be made on Teesside have also been secured in hopes the MHRA could approve it within weeks.
The results come on January 30th, the anniversary of the first known death from Covid-19 in the UK, that of 84-year-old Peter Attwood of Chatham, Kent.
A year later, the government announced on Friday that the death toll now stands at 104,371 after it was reported an additional 1,245 people had died within 28 days of testing positive for Covid-19.
Separate figures released by the UK statistical authorities for deaths where Covid-19 was mentioned on the death certificate, as well as additional data on deaths that have occurred in the past few days, show that there are now 121,000 deaths from Covid-19 in the UK. 19 gave.
Sign up below to find the vaccination center closest to you
However, recent government figures suggest that the growth rate, which estimates how quickly the number of infections changes from day to day, is between minus 5% and zero for the whole of the UK.
This means that the number of new infections in the UK is largely flat or is decreasing by up to 5% every day.
The Emergency Scientific Advisory Group (Sage) said the estimates are based on the latest data available as of Jan. 25, including hospital admissions and deaths, as well as symptomatic tests and prevalence studies.
However, she warned that cases “remain dangerously high and the public must remain vigilant to keep this virus under control, protect the NHS and save lives”.
Meanwhile, 8,369,438 coronavirus jabs were administered in the UK on Jan. 28, 7,891,184 of which were first doses – an increase of 443,985 from the previous day’s numbers.
The seven day moving average of the first doses given in the UK is now 358,297.
According to the latest figures, it would take an average of 418,166 first doses of vaccine per day to meet the government’s goal of 15 million first doses by February 15.


Leave a Comment